Improving vaccine supply and development: Who needs what? The answers might lie in a hybrid public-private model for financing, developing, and distributing vaccines

Health Affairs

Volumn 24, Issue 3, 2005, Pages 680-689

  Pauly, Mark V ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VACCINE;

CONSUMER; COST OF ILLNESS; DEVELOPING COUNTRY; DRUG COST; DRUG MANUFACTURE; DRUG MARKETING; FINANCIAL MANAGEMENT; GOVERNMENT; HUMAN; MARKETING; ORGANIZATION AND MANAGEMENT; REVIEW; UNITED STATES;

DRUG INDUSTRY; FINANCING, ORGANIZED; PRIVATE SECTOR; PUBLIC SECTOR; UNITED STATES; VACCINES;

EID: 20044392167     PISSN: 02782715     EISSN: None     Source Type: Journal    
DOI: 10.1377/hlthaff.24.3.680     Document Type: Review

References (9)

1. Institute of Medicine, Calling the Shots: Immunization Finance Policies and Practices (Washington: National Academies Press, 2000).
2. IOM, Financing Vaccines in the Twenty-first Century: Assuring Access and Availability (Washington: National Academics Press, 2004). The bulk of this decline occurred in the late 1970s and early 1980s; the reduction in suppliers has been slower but continuous since then.
3. Financing Vaccines in the Twenty-first Century: Assuring Access and Availability Ibid., 4.
4. Financing Vaccines in the Twenty-first Century: Assuring Access and Availability Ibid., 130-131.
5. B. Kaye, "Manufacturers' Perspective" in Vaccine Financing Stakeholders' Forum: NVPO Responds to the IOM Report, Washington, D.C., 28 June 2004, www.os.dhhs.gov/nvpo/meetings/jun2004/vaccinefinancing.html (22 March 2005).
6. M.V. Pauly and P.J. Held, "Benign Moral Hazard and the Cost-Effectiveness Analysis of Insurance Cover age," Journal of Health Economics 9, no. 4 (1990): 447.
7. IOM, Financing Vaccines;
8. and M. Kremer, "Creating Markets for New Vaccines," NBER Working Paper no. 7716 (Cambridge, Mass.: National Bureau of Economic Research, 2000).
9. IOM, Financing Vaccines, 16-18.